Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial
Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial
复制标题
DOI：
10.1038/jhh.2009.107
复制
发表时间：
2010-09-01
影响因子：
2.7
通讯作者：
Charney, A. N.
中科院分区：
文献类型：
--
作者：
Duprez, D. A.;Munger, M. A.;Charney, A. N.
比较直接肾素抑制剂阿利吉仑与雷米普利治疗老年原发性收缩期高血压的疗效和安全性。在901例年龄≥ 65岁、收缩压（SBP）≥ 140 mm Hg的患者（阿利吉仑，n = 457;雷米普利，n = 444）中进行了一项为期36周、随机、双盲、平行组、活性对照、选择性滴定研究。阿利吉仑150-300 mg/天或雷米普利5-10 mg/天给药12周，第12周可选添加氢氯噻嗪（12.5-25 mg/天），第22周可选添加替吉奥（5-10 mg/天）。主要终点是第12周平均坐位SBP（msSBP）较基线变化方面，阿利吉仑与雷米普利单药治疗的非劣效性。阿利吉仑单药治疗的msSBP和平均坐位舒张压较基线的降低（分别为14.0和-5.1 mmHg）是非劣效性的（P
Efficacy and safety of the direct renin inhibitor aliskiren was compared with ramipril for treatment of essential systolic hypertension in elderly patients. A 36-week, randomized, double-blind, parallel-group, active-controlled, optional-titration study was performed in 901 patients (aliskiren, n = 457; ramipril, n = 444) >= 65 years of age with systolic blood pressure (SBP) >= 140 mm Hg. Aliskiren 150-300 mg per day or ramipril 5-10 mg per day for was administered for 12 weeks with optional add-on therapy of hydrochlorothiazide (12.5-25 mg per day) at week 12 and amlodipine (5-10 mg per day) at week 22. The primary end point was non-inferiority of aliskiren vs ramipril monotherapy for change from baseline in mean sitting SBP (msSBP) at week 12. Decreases from baseline msSBP and mean sitting diastolic BP with aliskiren monotherapy (14.0 and -5.1 mm Hg, respectively) were non-inferior (P